Last reviewed · How we verify
NCT04022148
The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years
trial testing Gardasil in Cancer of Cervix in 2,800 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | University of Fukui |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 2,800 |
| Start date | 1 August 2019 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 December 2020 |
Drugs / interventions tested
- Gardasil — full drug profile →
Conditions studied
- Cancer of Cervix — all drugs for Cancer of Cervix →
- Vaccinia — all drugs for Vaccinia →
Sponsor
University of Fukui
Who can join
Adults 27 to 45, female only, with Cancer of Cervix or Vaccinia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A nonrandomized, non-double blinded prospective cohort study to evaluate the preventive efficacy of quadrivalent HPV6/11/16/18 vaccine for the persistent infection of HPV16 genotype or HPV18 genotype in Japanese women aged 27-45 years.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Is the catch-up program of HPV vaccination for Japanese adult women effective or not?
Kurokawa T. · · 2020 · cited 1× · PMID 32101628 · DOI 10.1111/cas.14342 -
The study protocol of the evaluation for the preventive efficacy of the HPV vaccine for persistent HPV16/18 infection in Japanese adult women: the HAKUOH study.
Kurokawa T, Yamamoto M, Onuma T, Tsuyoshi H, et al · · 2020 · PMID 33143690 · DOI 10.1186/s12885-020-07563-0
Verify or expand the search:
- PubMed search for NCT04022148
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Gardasil
Trials testing the same drug.
- NCT06142461 — Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System · Phase 2 · withdrawn
- NCT03998254 — Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) · Phase 3 · active not recruiting
- NCT04453241 — Immunogenicity and Safety Study of NBP615 in Healthy Female · Phase 1, PHASE2 · completed
- NCT03083249 — Gardasil Knowledge · completed
- NCT01914367 — Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) · Phase 4 · completed
Other recruiting trials for Cancer of Cervix
Currently open trials in the same condition.
- NCT05179824 — Tempus Priority Study: A Pan-tumor Observational Study · active not recruiting
- NCT05709730 — Follow-up of Cell Changes in the Cervix · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04022148 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Fukui
- Last refreshed: 19 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04022148.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing